Augmentative dopaminergic interventions for treatment-resistant bipolar depression: A focus on dopamine agonists and stimulants

Journal of Psychopathology

Volumn 19, Issue 4, 2013, Pages 327-340

  Dell'Osso, B ^a   Cremaschi, L ^a   Spagnolin, G ^a   Ketter, T A ^b   Altamura, A C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Armodafinil; Bipolar depression; Bipolar disorder; Dopamine agonists; Methylphenidate; Modafinil; Pramipexole; Ropinirole; Stimulants

Indexed keywords

EID: 84894142150     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the longterm course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008;108:49-58.
2. Ghaznavi S, Deckersbach T. Rumination in bipolar disorder: evidence for an unquiet mind. Biol Mood Anxiety Disord 2012;23;2:2.
3. Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat 2012;2012:684725.
4. Ghaemi SN, Soldani F, Hsu DJ. Evidence-based pharmacotherapy of bipolar disorder. Int J Neuropsychopharmacol 2003;6:303-8.
5. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr 2008;13:790-5.
6. Yatham LN, Kennedy SH, Schaffer A, et al. CANMAT and ISBD collaborative update of CANMAT guidelines for the manegement of patients with bipolar disorder. Bipolar Disord 2009;11:225-55.
7. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109.
8. Bennett JP Jr, Piercey MF. Pramipexole. A new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999;163:25-31.
9. Antonini A, Calandrella D. Pharmacokinetic evaluation of Pramipexole. Expert Opin Drug Metab Toxicol 2011;7:1307-14.
10. Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003;110:1119-27.
11. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992;31:937-46.
12. Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, Pramipexole. Psychopharmacology (Berl) 1994;115:454-62.
13. Maj J, Rogóz Z, Skuza G, et al. Antidepressant effects of Pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997;104:525-33.
14. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of Pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
15. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of Pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6.
16. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
17. Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
18. Möller JC, Oertel WH, Köster J, et al. Long-term efficacy and safety of Pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005;20:602-10.
19. Barone P, Scarzella L, Marconi R, et al. Pramipexole ver sus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-7.
20. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008;2:CD006722.
21. Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother 2009;43:1084-95.
22. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711-21.
23. Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 1980;137:963-5.
24. Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987;28:455-61.
25. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-502.
26. Schmitt KC, Reith ME. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 2011;6:e25790.
27. Vosburg SK, Hart CL, Haney M, et al. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 2010;106:233-6.
28. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005;353:476-86.
29. EMEA. Questions and answers on the review of medicines containing Modafinil. London: European Medicines Agency, EMA/725532/2010.
30. Ketter TA, Wang PW. Overview of pharmacotherapy for Bipolar Disorder. In: Ketter T, editor. Handbook of diagnosis and treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing 2010, pp. 83-106.
31. Ketter TA, Wang PW. Antidepressants, anxiolytic/hypnotics and other medications: pharmacokinetics, drug inetractions, adverse effects and administration. In: Ketter T, editor. Handbook of diagnosis and treatment of Bipolar Disorder. Washignton, DC: American Psychiatric Publishing 2010, pp. 611-60.
32. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43-64.
33. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull 2008;41:37-47.
34. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition. Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88.
35. Pfennig A, Bschor T, Baghai T, et al. S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt 2012;83:568-86.
36. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999;156:798.
37. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-40.
38. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: US Dept. of Health, Education and Welfare 1976.
39. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-41.
40. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;4:307-14.
41. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
43. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiat 1978;133:429.
44. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004;20:131-8.
45. Gupta S, Vincent JL, Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectr 2006;11:172-5.
46. Akdeniz F, Aldemir E, Vahip S. The role of low-dose Pramipexole in the treatment of treatment-resistant bipolar depression: a case report. Turk Psikiyatri Derg 2009;20:94-8.
47. El-Mallakh RS, Penagaluri P, Kantamneni A, et al. Long-term use of Pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q 2010;81:207-13.
48. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766.
49. Burdick KE, Braga RJ, Nnadi CU, et al. Placebo-controlled adjunctive trial of Pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012;73:103-12.
50. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord 2000;2:56-59.
51. Bigelow LB, Berthot BD. The psychiatric symptom assessment scale (PSAS). Psychopharmacol Bull 1989;25:168-79.
52. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004;6:416-20.
53. Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol 2006;26:516-8.
54. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand 2010;121:308-14.
55. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61:378-81.
56. Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother 2003;37:1807-9.
57. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
58. Nasr S. Modafinil as adjunctive therapy in depressed outpatients. Ann Clin Psychiatry 2004;16:133-8.
59. Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006;95:111-4.
60. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-9.
61. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18:65-87.
62. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71:1363-70.
63. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007;68:1230-6.
64. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998;59:60-4.
65. Erfurth A, Michael N, Stadtland C, et al. Bupropion as addon strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 2002;45:33-6.
66. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(Suppl.3):S7-14.
67. Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000;5:378-88.
68. Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998;71:295-301.
69. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by Pramipexole. J Neural Transm 1997;104:209-28.
70. Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord 2001;7:213-23.
71. Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist Pramipexole. Curr Med Res Opin 2009;25:2977-87.
72. Belmaker RH. Modafinil add-on in the treatment of bipolar depression. Am J Psychiatry 2007;164:1143-5.
73. Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-67.
74. Fountoulakis KN, Siamouli M, Panagiotidis P, et al. Ultra short manic-like episodes after antidepressant augmentation with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:891-2.
75. Maremmani I, Pacini M, Lamanna F, et al. Mood stabilizers in the treatment of substance use disorders. CNS Spectr 2010;15:95-109.
76. Plante DT. Treatment-emergent hypomania or mania with modafinil. Am J Psychiatry 2008;165:134-5.
77. DelBello MP, Soutullo CA, Hendricks W, et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord 2001;3:53-7.
78. Soutullo CA, DelBello MP, Ochsner JE, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord 2002;70:323-7.
79. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67:554-66.
80. Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychopharmacol 1999;14:1-18.
81. Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991;32:203-8.
82. Rosenberg PB, Ahmed I, Hurwitz S. Methylphenidate in depressed medically ill patients. J Clin Psychiatry 1991;52:263-7.
83. Rozans M, Dreisbach A, Lertora JJ, et al. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002;20:335-9.
84. Wallace AE, Kofoed LL, West AN. Double-blind, placebocontrolled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995;152:929-31.
85. Manove E, Levy B. Cognitive impairment in bipolar disorder: an overview. Postgrad Med 2010;122:7-16.
86. Sawaguchi T. The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci Res 2001;41:115-28.
87. Morein-Zamir S, Turner DC, Sahakian BJ. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 2007;33:1298-306.
88. Repantis D, Schlattmann P, Laisney O, et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;62:187-206.